{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-020896","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2026-05-13T00:39:53+00:00","discovered_at":"2026-05-13T10:10:00.321814+00:00","generated_at":"2026-05-13T10:21:51.736475+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US","bullets":["Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.","R&D expenses $17.5M, driven by clinical trial costs, manufacturing process validation, and headcount expansion.","Completed $320M capital raises in January 2026 to support PARADIGM Trial and global commercialization of DurAVR THV.","Post quarter-end, US patient enrollment in the PARADIGM Trial commenced; CMS coverage determination supports reimbursement.","Presented EMBARK Study and EFS data at CRT 2026 and Sydney Valves 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020896","json":"https://secwatch.observer/filing/0001140361-26-020896.json","markdown":"https://secwatch.observer/filing/0001140361-26-020896.md","text":"https://secwatch.observer/filing/0001140361-26-020896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126020896/0001140361-26-020896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126020896/ef20072992_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T10:21:51.736475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"138a788d1f806ec6f732ab31e2bdb7c3f092e56a","claim":"Anteris Technologies Global Corp. reported financial results for first quarter of 2026.","evidence_excerpt":"today reported financial results for the quarter ended 31 March 2026, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126020896/0001140361-26-020896-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}